Introduction {#s1}
============

ATM kinase is a tumor suppressor that has a central role in the DNA damage responses. Germline inactivation of ATM causes ataxia-telangiectasia (A-T), which is associated with greatly increased risk of lymphoma and leukemia ([@bib37]). Somatic mutations of ATM occur frequently in mantle cell lymphomas (MCL), chronic lymphoblastic leukemia (CLL) and T-cell prolymphocytic leukemia (TPLL) ([@bib68]; [@bib6]; [@bib64]). In lymphomas, *ATM* mutations often occur with concurrent heterozygous deletion of 11q23 including *ATM* ([@bib68]; [@bib6]; [@bib64]), potentially leading to the expression of mutated ATM in the absence of the wild-type (WT) protein. Recent sequencing studies also identified recurrent ATM mutations in 2--8% of breast, pancreas or gastric cancers ([@bib56]; [@bib16]). While the majority of A-T patients (\~90%) have *truncating ATM* mutations that result in little or no ATM protein expression ([@bib15]), missense *ATM* mutations are more common in cancers and with the exception of the few that cause A-T, their biological functions are unknown.

As a serine/threonine protein kinase, ATM is recruited and activated by DNA double strand breaks (DSBs) through direct interactions with the MRE11, RAD50 and NBS1 (MRN) complex ([@bib38]; [@bib46]; [@bib63]; [@bib12]). Activated ATM phosphorylates \>800 substrates implicated in cell cycle checkpoints, DNA repair, and apoptosis to suppress genomic instability and tumorigenesis. ATM activation is also associated with inter-molecular autophosphorylation ([@bib3]; [@bib36]). Studies in human cells suggest that auto-phosphorylation is required for ATM activation ([@bib3]; [@bib36]). However, alanine substitutions at one or several auto-phosphorylation sites do not measurably affect ATM kinase activity in transgenic mouse models ([@bib18]; [@bib48]), leaving the biological function of ATM auto-phosphorylation unclear. In this context, we and others generated mouse models expressing kinase dead (KD) ATM protein (Atm-KD) ([@bib71]; [@bib17]). In contrast to the normal development of *Atm*^-/-^ mice, *Atm*^KD/-^ and *Atm*^KD/KD^ mice die during early embryonic development with severe genomic instability ([@bib71]; [@bib17]; [@bib4]), implying that the expression of Atm-KD in the absence of WT ATM further inhibits DNA repair beyond the loss of ATM. Among the major DNA DSB repair pathways, non-homologous end-joining (NHEJ) is uniquely required for the repair phases of lymphocyte specific V(D)J recombination and class switch recombination (CSR). ATM promotes NHEJ ([@bib76]; [@bib8]), and *Atm*^-/-^ mice and A-T patients suffer from primary immunodeficiency ([@bib29]; [@bib75]). The end-joining defects in V(D)J recombination and CSR are similar in *Atm*^KD/-^ and *Atm*^-/-^ lymphocytes, suggesting that Atm-KD protein is not dominant-inhibitory for NHEJ. Meanwhile, *Atm*^KD/-^ cells show moderate yet significant hypersensitivity to PARP inhibitors in comparison to both *Atm*^-/-^ and *Atm*^+/+^ cells ([@bib17]), and ATM kinase inhibitor, but not loss-of-ATM, reduced homologous recombination (HR) as measured by sister chromatid exchange (SCE) ([@bib69]) and the DR-GFP HR reporter ([@bib52]; [@bib31]), suggesting a role of ATM auto-phosphorylation in replication associated homology dependent repair. Yet, it is unknown how ATM auto-phosphorylation contributes to DNA replication and HR beyond its previously identified signaling roles. Finally, consistent with the \'inter\'-molecular autophosphorylation model, *Atm*^+/KD^ mice are largely normal ([@bib71]), suggesting that *ATM*^KD^ mutation carriers could be asymptomatic and somatic loss of the WT allele in the carriers might create the Mut/Del status reported in human cancers and lymphomas.

Here we report that 72% of human cancer-associated ATM mutations are missense mutations that are highly enriched in the kinase domain. We further show that conditional expression of Atm-KD protein alone (somatic inactivation of the conditional allele (*Atm*^C^) in *Atm*^KD/C^ mice to generate the *Atm*^KD/-^ cells) in murine hematopoietic stem cells (HSCs) is more oncogenic than the complete loss of ATM (*Atm*^-/-^). *Atm*^KD/-^ cells are selectively hypersensitive to Topo Isomerase I (Topo1) inhibitors, in part because the Atm-KD protein physically blocks replication-dependent strand cleavage upon Topo1 inhibition. Correspondingly, Topo1 inhibitor selectively eradicates Notch1-driven *Atm*^KD/-^ leukemia, but not the isogenic parental Atm proficient leukemia, identifying Topo1 inhibitors as a *targeted* therapy for human cancers carrying missense ATM kinase domain mutations.

Results {#s2}
=======

Cancer-associated ATM mutations are enriched for kinase domain missense mutations {#s2-1}
---------------------------------------------------------------------------------

Among the 5402 cases in The Cancer Genome Atlas (TCGA), we identified 286 unique non-synonymous mutations of *ATM*. While truncating (nonsense/frameshift) mutations compose 83% (373/447) of A-T associated point mutations (\>1000 patients), 72% (206/286) of non-synonymous point mutations of *ATM* in TCGA are missense mutations ([Figure 1A](#fig1){ref-type="fig"}, [Supplementary file 1A,B](#SD1-data){ref-type="supplementary-material"}). Permutation analyses show that *ATM* gene is not hyper-mutated, but the kinase-domain is mutated 2.5 fold more frequently than otherwise expected in TCGA ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, p\<0.01). The mutation density calculated using the Gaussian Kernel model revealed that cancer associated missense *ATM* mutations in TCGA cluster around the C-terminal kinase domain, while truncating mutations (in A-T or TCGA) span the entire ATM protein ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Given the severe phenotype of *Atm*^KD/-^, but not *Atm*^KD/+^ cells, we further analyzed the subset (\~105/286) of *ATM* missense mutations in TCGA that are concurrent with heterozygous loss of *ATM* (shallow deletion) or truncating mutations in the same case, and found that, again, *ATM* missense mutations cluster around the C-terminal kinase domain even in this smaller subset ([Figure 1B](#fig1){ref-type="fig"}). The kinase and FATC domains of ATM share 31% sequence identity with mTOR, a related phosphatidylinositol 3-kinase-related protein kinase (PIKK) for which the high resolution crystal structure is available ([@bib72]). Homology modeling using mTOR (PDB 4JSP) ([@bib72]) revealed that 64% (27/42) (at 18 unique amino acids) of ATM kinase domain missense mutations from TCGA, affect highly conserved residues and 50% (21/42) of the mutations (red on the ribbon structure) likely abolish kinase activity based on structural analyses ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Specifically, residues K2717, D2720, H2872, D2870, N2875 and D2889 of human ATM are predicted to bind ATP or the essential Mg^+^ ion ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Notably, N2875 is mutated in two TCGA cases at the time of initial analyses. One of the two cases have concurrent shallow deletion in this region ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}). Since then, one additional N2875 mutation was reported in a prostate cancer case (TCGA-YL-A8S9) with an allele frequency of 0.92, consistent with homozygosity. Mutations corresponding to N2875K of human ATM were previously engineered into the *Atm*^KD/+^ mice together with the corresponding D2870A mutation of human ATM. This combination was found to abolish ATM kinase activity without significantly affecting ATM protein levels ([@bib71] [@bib71]; [@bib11]). Finally, immunoblotting confirmed the expression of catalytically inactive ATM protein in several human cancer cell lines with missense mutations around the kinase domain (CCLE, Broad Institute) ([Figure 1---figure supplement 1E--F](#fig1s1){ref-type="fig"}).10.7554/eLife.14709.003Figure 1.Cancer-associated ATM mutations are enriched for kinase domain missense mutations.(**A**) Classification of unique and nonsynonymous mutations reported for A-T patients (n \> 1000) in the Leiden open variable database (<http://chromium.lovd.nl/LOVD2/home.php?select_db=ATM>) ([Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}) or unique mutations from 5402 cancer cases in TCGA ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}). \'Others\' includes splice-site and stop codon mutations. (**B**) Heatmaps for the frequency of cancer-associated truncating mutations (upper panel) or nonsynonymous substitutions (missense) mutations (lower panel) along the human ATM polypeptide obtained using Gaussian kernel based analyses (see Materials and methods). Warmer colors indicate denser mutation distribution. The shadowed curves in the middle and the bottom panel reflect the ratio of actual over expected mutation frequencies, calculated by Gaussian kernel method in all TCGA ATM missense mutations (middle) or only missense mutations with concurrent shallow deletion/truncating mutations (bottom). The confidence intervals (shadows) are estimated by fitting a binomial distribution (see Materials and methods). The dashed line at 1 represents the expected rate of mutations. The x-axis is the amino acid number (from 1--3057, including stop code) along the human ATM protein. (**C**) Homology model of the human ATM kinase domain is shown in two views rotated by 90°. The N-lobe (aa 2640--2774) is shown in green; the C-lobe (aa 2775--3057,) is shown in yellow; the activation loop (aa 2883--2907) is shown in cyan; the FATC domain (aa 3029--3056) is shown in purple and the ka9b (aa 2942--2956) and ka10 (aa 3002--3026) is shown in pink. The αC-helix (aa 2722--2741), which is a part of the N-lobe and contains residues critical for catalysis is shown in blue. ATP and residues critical for catalysis are shown in the stick model. Mg^2+^ ions are shown as spheres. The black dotted loops indicate the disordered region between ka9b and ka10. The amino acids that are conserved between human ATM and mTOR and mutated in TCGA cases are shown in red.**DOI:** [http://dx.doi.org/10.7554/eLife.14709.003](10.7554/eLife.14709.003)10.7554/eLife.14709.004Figure 1---figure supplement 1.Cancer associated ATM mutations are enriched for kinase domain missense mutations that disrupt kinase activity.(**A**) Permutation analyses of actual truncation or missense mutation frequencies within the ATM gene or within the ATM kinase domain over the expected mutation frequency based on the size of the gene and the frequency of non-synonymous mutation. The dash line marks the expected mutation rate. (**B**) The density distribution of truncation/frame shift mutations in A-T patients (see [Figure 1B](#fig1){ref-type="fig"} legend and method for more details). (**C**) Superposition of the human ATM model (yellow) and the crystal structure of human mTOR (blue) suggest close structural homology, especially around the catalytic center. Mutations conserved between ATM and mTOR are shown in red. (**D**) The active site architecture of human ATM predicted based on homology modeling is colored as follows: ATP is shown in red, Mg^2+^ ion is shown in purple, the catalytic residues from ATM are shown in blue and the substrate is colored black. (**E**) Table with the annotated ATM mutations in selected human cancer cells. (**F**) Western blots of total cell lysates harvested from the indicated human tumor lines for ATM (upper), and pKap1 (lower) with (+) or without (-) 5 Gy Irradiation (IR).**DOI:** [http://dx.doi.org/10.7554/eLife.14709.004](10.7554/eLife.14709.004)

Expression of Atm-KD is more oncogenic than loss of Atm {#s2-2}
-------------------------------------------------------

To determine the oncogenic properties of ATM-KD protein and circumvent the embryonic lethality of the *Atm*^KD/-^ mice ([@bib71]), we generated littermate matched *VavCre*^+^*Atm*^C/KD ^(VKD) and *VavCre*^+^*Atm*^C/C^ (VN, N for null) mice. In these mice, the HSC-specific Cre recombinase (*VavCre*) ([@bib19]) efficiently inactivates the Atm conditional (*Atm*^C^) allele ([@bib77]; [@bib10]) in all blood cells including lymphocytes ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). VKD and VN mice display defects in B cell CSR and T cell development similar to *Atm*^-/-^ mice, namely 50% decrease of CSR (to IgG1), reduced expression of surface-TCRβ/CD3 in CD4^+^CD8^+^ double-positive (DP) cells, and partial blockage at DP to CD4^+^CD8^-^ or CD4^-^CD8^+^ single-positive (SP) T cell transitions ([@bib7]; [@bib41]; [@bib54]) ([Figure 2---figure supplement 1B--C](#fig2s1){ref-type="fig"}), supporting efficient inactivation of *Atm*^C^ allele in VKD and VN lymphocytes. Immature T cells with productive TCRβ rearrangements undergo rapid proliferation and expansion in the CD4^-^CD8^-^ double-negative (DN) 3 stage (CD44^-^CD25^+^). VKD thymocytes, but not VN or *Atm*^-/-^ thymocytes, are partially blocked at the DN3 stage, consistent with proliferation defects in *Atm*^KD/-^ cell ([@bib71]) ([Figure 2A--B](#fig2){ref-type="fig"}). As a result, thymocyte number in VKD mice was reduced \~60% compared to their VN littermates ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}).10.7554/eLife.14709.005Figure 2.Expression of ATM-KD protein (Atm^KD/-^) is more oncogenic than loss of ATM (Atm^-/-^).(**A**) Representative FACS analyses of DN thymocytes from 4-week old *VavCre-Atm*^C/KD^ (Ctrl, littermate), germline Atm-knockout (*Atm*^-/-^), *VavCre*^+^*Atm*^C/C^ (VN) and *VavCre*^+^*Atm*^C/KD^ (VKD) mice. DN cells are defined as thymocytes negative for surface staining of CD8, CD4 and TCRγδ. (**B**) The average relative DN3% (CD44^-^CD25^+^) (among all DN thymocytes) in VN (n = 3) and VKD (n = 4) mice. The relative DN3% was calculated by normalizing to the absolute DN3% to the DN3% of control littermate *VavCre*^-^ (cre negative) mice stained at the same time. The error bars represent SEMs. (**C**) The averages and standard SEMs of total thymocyte number from 4--8 weeks old VN (n = 3) and VKD (n = 3) mice. (**D**) The life time risk of B or T cell lymphomas in VN, VKD mice in 400 days. (**E**) Kaplan-Meier (K-M) survival curve of littermate matched VN (n = 18) and VKD (n = 24) mice. The red and blue dots denote thymic lymphomas from the VN and VKD cohorts, respectively. The yellow dots denote the B cell lymphomas in the VKD cohort. The T~1/2~ for thymic lymphoma is 139.5 days (VN) and 104.0 days (VKD). The asterisk marks the difference in T~1/2~ of thymic lymphoma development between the two cohorts. \*p=0.03 per Mantel-Cox/log-rank test. (**F**) Copy number analyses of the region around *Pten* (chromosome 19, *mm8: 32,779,983--32,908,796*). The y-axis is the natural log ratio of tumor/kidney genomic DNA from the same mouse. Log ratio of −0.67 (dotted line) indicates heterozygous deletion. (**G**) Immunoblot of Pten, total Atm and β-actin for *Atm*^+/+^ (WT Thy), VKD, and VN thymic lymphomas. (**H**) Telomere FISH analyses of metaphases spreads from ConA activated T-cells (72 hr). Bar graphs represent the average and SEMs of the number of cytogenetic aberrations per metaphase (MP). All p-values in this figure were calculated using a two-tailed student's t-test assuming unequal variances, unless otherwise noted.**DOI:** [http://dx.doi.org/10.7554/eLife.14709.005](10.7554/eLife.14709.005)10.7554/eLife.14709.006Figure 2---figure supplement 1.Lymphocyte development in VKD and VN mice.(**A**) Southern Blot for the Atm conditional vs deleted allele in kidney, bone marrow, splenocytes, thymocytes and activated splenic B cells (CD43^-^, LPS stimulated) of a representative VN mouse, indicating complete deletion of Atm in lymphoid lineage. KpnI-digested genomic DNA was probed with ATMCKO3' probe. (**B**) Representative FACS analyses of bone marrow, thymus and spleen show normal B cell and myeloid development, thymocyte development defects and CSR defects in VN and VKD mice. (**C**) Quantification of IgG1^+^% of purified B cells stimulated with LPS and IL-4 for 4.5 days. (**D**) FACS analyses of thymocytes harvested from VN and VKD mice with thymic lymphomas. The dash line marks the level of surface TCRβ expression in control thymocytes. (**E**) Southern blot analyses of thymocyte DNA digested with EcoRI and probed with TCRJβ1.6 and TCRJβ2.7 probes. Marker: Molecular Weight Marker. Ctrl: Kidney DNA harvested from a *VavCre- Atm*^C/KD^ mouse, GL-Germline.**DOI:** [http://dx.doi.org/10.7554/eLife.14709.006](10.7554/eLife.14709.006)10.7554/eLife.14709.007Figure 2---figure supplement 2.Analyses of the T cell lymphomas from VKD and VN mice.(**A**) CGH analyses of 4 VKD and 1 VN thymic lymphomas. The Y axis is the Log ratio (base 2) of tumor/kidney DNA from the same mouse. The red arrow heads indicate trisomy 15 and regions amplified on chromosome 14, and the green arrow heads point to the deletion in chromosomes 12 and the deletion around the *Pten* gene. Each chromosome is demarcated by gray lines, and the chromosome numbers are marked at the top of the CGH panels. (**B**) Representative FACS analyses of the splenocytes from control and two VKD mice with B-cell lymphomas. (**C**) Southern blot analyses of splenocyte DNA harvested from VKD mice with B-cell lymphomas digested with EcoRI and probed using JH4, Myc-A, and TCRJβ1.6 probes. Ctrl: Kidney DNA harvested from a VavCre- Atm^C/KD^ mouse, GL-Germline.**DOI:** [http://dx.doi.org/10.7554/eLife.14709.007](10.7554/eLife.14709.007)

Despite low thymocyte counts, 75% of VKD mice succumbed to lymphomas, representing a 34% increase over the 56% life-time risk among VN mice ([Figure 2D](#fig2){ref-type="fig"}). Furthermore, the median survival of thymic lymphoma bearing VKD mice is \~35 days shorter than that of VN mice (104 and 139 days respectively, p=0.03) ([Figure 2E](#fig2){ref-type="fig"}). The thymic lymphomas from the VN mice and VKD mice are both clonal, immature (TCRβ/CD3^low^) ([Figure 2---figure supplement 1D--E](#fig2s1){ref-type="fig"}) with frequent trisomy 15, have focal amplifications around the TCRα/δ loci, and have hemizygous deletion of the telomeric portion of chromosome 12, as is the case for previously characterized *Atm*^-/-^ thymic lymphomas ([@bib29]; [@bib74]) ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). About 8% of the VKD, but none of the VN mice, also developed clonal pro-B cell lymphomas (B220^+^CD43^+^IgM^-^) ([Figure 2---figure supplement 2B--C](#fig2s2){ref-type="fig"}). Comparative genome hybridization (CGH) showed that all VKD thymic lymphomas, but none of the VN controls, carried deep deletions at the *Pten* locus ([Figure 2F](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). Immunoblotting of additional lymphomas revealed severe reductions of Pten protein levels in all but one of the VKD tumors, while most VN tumors retained Pten expression. The only Pten-expressing VKD tumor (6684) appeared to have lost Atm-KD expression ([Figure 2G](#fig2){ref-type="fig"}). *Pten* deletion was previously found in \~25% of germline *Atm*^-/-^ or *Tp53*^-/-^ thymic lymphomas and was thought to occur in the early progenitors before T cell commitment ([@bib74]; [@bib23]). Based on our findings, we propose that expression of Atm-KD protein further increases genomic instability in lymphoid progenitors/HSCs, eventually led to frequent *Pten* deletion and early lymphomas in the VKD mice. Consistent with this model, frequency of chromatid breaks are significantly higher in VKD T cells, than in VN or *Atm*^+/+^ T cells ([Figure 2H](#fig2){ref-type="fig"}).

*Atm*^KD/-^ cells and *Atm*^KD/-^ leukemia are hypersensitive to Topo-isomerase I inhibitors {#s2-3}
--------------------------------------------------------------------------------------------

We hypothesized that the additional DNA repair defects in Atm^KD/-^ cells would confer hypersensitivity to certain genotoxic chemotherapy that could be used to target ATM-mutated cancers. To test this, we derived *Rosa*^+/CreERT2^*Atm*^+/C^, *Rosa*^+/CreERT2^*Atm*^C/-^ and *Rosa*^+/CreERT2^*Atm*^C/KD^ murine embryonic fibroblasts (MEFs), in which 4-Hydroxytamoxifen (4-OHT, 200 nM) induces nuclear translocation of ER-fused Cre-recombinase and effectively inactivates the *Atm*^C^ allele to generate *Atm*^+/-^, *Atm*^-/-^ and *Atm*^KD/-^ MEFs ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) ([@bib71]). All the experiments were repeated ≥3 times in several independently derived and freshly deleted cells to avoid secondary alterations in genomically unstable Atm-deficient cells. While both *Atm*^KD/-^ and *Atm*^-/-^ MEFs were similarly sensitive to ionizing radiation (IR), *Atm*^KD/-^ cells were significantly more sensitive to the Topo1 inhibitor camptothecin (CPT) than *Atm*^-/-^ and *Atm*^+/-^ cells ([Figure 3A--B](#fig3){ref-type="fig"}). The CPT hypersensitivity of *Atm*^KD/-^ cells does not appear to reflect an inability to process blocked DNA ends or overcome replication blockage in general, as *Atm*^KD/-^ cells were not hypersensitive to etoposide, a Topoisomerase *II* inhibitor, nor to two replication blocking agents, hydroxyurea (HU) or aphidicolin (APH), ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Moreover, *Atm*^KD/-^ primary T cells and the human cancer cell lines that express ATM-KD protein identified in [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"} are also hypersensitive to CPT compared to corresponding *ATM*^+/+^ or *Atm*^-/-^ controls ([Figure 3D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). Finally, shRNA knockdown of mutated ATM in Granta519 human lymphomas cell lines, moderately, yet significantly, rescued the CPT hypersensitivity and CPT induced apoptosis associated with the expression of catalytically inactive ATM ([Figure 3E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1C and D](#fig3s1){ref-type="fig"}).10.7554/eLife.14709.008Figure 3.*Atm*^KD/-^ murine embryonic fibroblasts (MEFs) and human cancer cell lines are hypersensitive to Topo isomerase I inhibitors in vitro.Representative sensitivity plots of *Atm*^+/-^, *Atm*^-/-^ and *Atm*^KD/-^ MEFs to (**A**) IR, (**B**) Camptothecin (CPT) and (**C**) Etoposide. \*p\<0.001. At least three independent experiments on two independently derived MEF lines from each genotype were performed. (**D**) Sensitivity of 6 human tumor cell lines with wildtype (*ATM*^+/+^) or mutant ATM (*ATM*^Mut/-\ or\ Mut/Mut^) to 2.5 nM CPT observed after 48 hr of treatment. (**E**) shRNA mediated knockdown of ATM in Granta591 human lymphoma cell lines rescued the CPT sensitivity in vitro (after 72 hr of 5 nM CPT treatment). Three independent experiments were performed. The p value were obtained based on student t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.14709.008](10.7554/eLife.14709.008)10.7554/eLife.14709.009Figure 3---figure supplement 1.Analyses of immortalized *Atm*^KD/-^ and control MEFs.(**A**) Treatment scheme of immortalized Rosa-CreERT2 MEFs. PCR and Western blot analyses of the MEFs before and after three rounds of 4OHT treatment (200 nM, 48 hr each round) confirmed the efficient ATM deletion and the expression of kinase-dead ATM protein. The Western blot also shows the normal expression of DNA-PKcs, Mre11 and Kap1 in the Atm^KD/-^ cells. (**B**) Representative result of the sensitivity assay for Hydroxyurea and Aphidocolin. See method section for details. (**C**) Representative FACS analyses for apoptotic cells (PI staining) in HBL2 and Granta591 cells with or without shRNA knockdown of ATM. (**D**) CPT (5 nM, 48 hr) induced apoptosis in HBL2 and Granta591 cells measured by PI staining. (**E**) Relative survival of ConcanavalinA (ConA)-activated purified (CD43^+^) splenic T-cells to Olaparib (PARPi, 1 µM) or CPT (0.1 µM), or the combination (PARPi+CPT). Cells were stimulated for 24 hr and exposed to drugs for another 48 hr and relative survival was determined by MTT assay.**DOI:** [http://dx.doi.org/10.7554/eLife.14709.009](10.7554/eLife.14709.009)

In animal models, irinotecan, a clinical Topo1 inhibitor, eradicated activated-Notch1 (Notch1-ΔE-IRES-GFP) driven *Atm*^KD/-^ T cell leukemia, but not the isogenic parental *Atm*^KD/C^ leukemia in vivo, determined by the absence of GFP^+^ leukemia cells in the spleen, reduced spleen size and weight, lack of infiltrated leukemia blasts and increased TUNEL^+^ apoptotic cells ([Figure 4A--F](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}). When similar experiments were performed on isogenic *Atm*^C/C^ and corresponding *Atm*^-/-^ leukemia, irinotecan has no significant benefit in either groups ([Figure 4---figure supplement 1C--F](#fig4s1){ref-type="fig"}, p≥0.05 in all pairs), suggesting loss of ATM-mediated DNA damage responses alone is not sufficient to explain the hypersensitivity of *Atm*^KD/-^ leukemia to Topo1 inhibitors. Together these findings identified the expression of ATM-KD as a biomarker for Topo1 inhibitors sensitivity.10.7554/eLife.14709.010Figure 4.*Atm*^KD/-^ leukemia are hypersensitive to Topo isomerase I in vivo.(**A**) Experimental scheme outlining the treatment of isogenic *Atm*^KD/-^ and *Atm*^KD/C^ leukemia in vivo. Please see on-line methods for details. Clonal Rosa^+/CreERT2 ^Atm^C/KD^ leukemia was established by transducing the bone marrow with activated Notch and GFP. Isogenic *Atm*^KD/-^ or *Atm*^KD/C^ leukemia were then established and confirmed in secondary recipients upon exposure to oral tamoxifen, which induces Cre nuclear translocation. 1 × 10\^6 *Atm*^KD/-^ and *Atm*^KD/C^ leukemic blasts were injected into tertiary recipients, which were treated with daily doses of Irinotecan (10 mg/kg) or vehicle for 5 consecutive days. Representative FACS analyses for GFP^+^ leukemia blast (**B**) and pictures (**D**) of spleens from mice transduced with isogenic *Atm*^KD/C^ or *Atm*^KD/-^ leukemia and treated or not treated with irinotecan (Irino, 10 mg/Kg for 5 days). The untreated mice received vehicle (Veh). Quantification (Average ± SEMs) of GFP^+^% splenocytes (**C**) and spleen weights (**E**) of mice transduced with *Atm*^KD/C^ or *Atm*^KD/- ^leukemia and treated with either vehicle (black) or Irinotecan (grey) for 5 days. (**F**) Representative field of H&E (left 2 panels) and TUNEL-stained spleen sections Scale Bars: 200 µm (in H&E section), 20 µm (TUNEL).**DOI:** [http://dx.doi.org/10.7554/eLife.14709.010](10.7554/eLife.14709.010)10.7554/eLife.14709.011Figure 4---figure supplement 1.Analyses of isogenic paired *Atm*^KD/-^ vs *Atm*^KD/C^ or *Atm*^-/-^ vs *Atm*^C/C^ leukemia.(**A**) PCR confirming the *Atm*^KD/-^ and *Atm*^KD/C^ genotypes of the leukemia harvested from secondary recipients after the tamoxifen treatment. (**B**) Southern blot using the Jβ2.7 probe on *Atm*^KD/-^ and *Atm*^KD/C^ tumors harvested after vehicle (V) or Irinotecan (Iri) treatment. \*denoted degraded DNA. Spleens from Irinotecan treated mice with *Atm*^KD/-^ leukemia had very few leukemia cells and only the germline TCRβ bands. (**C**) Representative spleens harvested from tertiary recipients transduced with isogeneic *Atm*^C/C^ or *Atm*^-/-^ leukemia treated with either Vehicle (Veh) or Irinotecan. Quantification (Average ± SEMs) of GFP^+^% splenocytes (**D**) and spleen weights (**E**) of mice transduced with *Atm*^C/C^ or *Atm*^-/-^ leukemia and treated with either vehicle (black) or Irinotecan (grey) for 5 days. (**F**) Representative fields of H&E stained spleen sections. Scale Bars: 200 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.14709.011](10.7554/eLife.14709.011)

ATM-KD blocks replication-dependent removal of Topo-isomerase I DNA adducts at the step of strand cleavage {#s2-4}
----------------------------------------------------------------------------------------------------------

Topo1 inhibitors prevent DNA-religation by Topo1, and trap Topo1 in a covalent DNA complex (Top1cc) at the 3'-end of single-strand DNA (ssDNA) nicks generated by Topo1 cleavage ([@bib49]). If not removed, Top1cc interferes with transcription and replication to elicit cytotoxic effects. We found that *Atm*^KD/-^, but not *Atm*^-/-^ or *Atm*^+/+^ MEFs accumulated Top1cc even at low CPT concentrations (0.1 µM) ([Figure 5A](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A and B](#fig5s1){ref-type="fig"}). ATM kinase inhibitor (ATMi, KU55933, 15 µM) also leads to CPT-dependent Top1cc-accumulation in *Atm*^+/-^ MEFs ([Figure 5A](#fig5){ref-type="fig"}). At high CPT concentration (15 µM), the Top1cc level is greatest in *Atm*^KD/-^ cells, followed by *Atm*^-/-^, then *Atm*^+/+^([Figure 5A](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A and B](#fig5s1){ref-type="fig"}). Meanwhile, CPT-induced degradation of full-length Topo1, necessary for its subsequent removal ([@bib49]), is not significantly affected in *Atm*^KD/-^ or *Atm*^-/-^ MEFs ([Figure 5B](#fig5){ref-type="fig"}). Tyrosyl-DNA phosphodiesterase 1 (TDP1) or 3' flapase (*e.g.* XPF) can remove Top1cc independent of DNA replication ([@bib49]) ([Figure 5C](#fig5){ref-type="fig"}). In quiescent neurons, ATM promotes transcription-dependent removal of Top1cc potentially by facilitating Topo1 degradation independent of its kinase activity or MRN ([@bib2]; [@bib32]). While this function of ATM might contribute to the moderate accumulation of Top1cc in CPT treated *Atm*^-/-^ MEFs at high CPT concentrations ([Figure 5A](#fig5){ref-type="fig"}), the kinase-dependent and protein-dependent role of ATM in Top1cc removal revealed in proliferating *Atm*^KD/-^ MEFs appears to be independent of Topo1 degradation ([Figure 5B](#fig5){ref-type="fig"}). In this context, a recent study using Xenopus extract suggests that collision of the replication forks with protein conjugated to DNA would lead to rapid and robust proteolytic degradation of the conjugated proteins, which might mask the moderate effects of ATM in Top1cc-proteolytic degradation described in none proliferative neuronal cells ([@bib24]). During replication, it is proposed that the collision of the DNA replication forks with Top1cc blocks the replication on the involved strand, leads to uncoupling of the leading strand and lagging strand syntheses and fork reversal. Eventually a subset of the stalled replication forks are cleaved to remove Top1cc (as diagrammed in [Figure 5C](#fig5){ref-type="fig"}). The resulting single-ended DSBs generated from fork cleavage can only be repaired by HR, not NHEJ. Resolution of the holiday junction intermediates during HR generates crossover (CO), thus CPT is known to induce SCEs ([Figure 5C](#fig5){ref-type="fig"}). CPT (1 µM) induced SCEs were reduced in *Atm*^KD/-^ MEFs, but not *Atm*^-/-^ MEFs, and ATM inhibitor decreased CPT-induced SCEs in *Atm*^+/-^, but not in *Atm*^-/-^ MEFs ([Figure 5D](#fig5){ref-type="fig"}), suggesting a defect at replication-dependent removal of Top1cc in the *Atm*^KD/-^ cells. ATM kinase inhibitor did not suppress SCEs in Blmhelicase-deficient (*Blm*^-/-^) MEFs, suggesting that the lack of SCEs could not be simply explained by the bias in CO-generating holiday junction resolvases (*e.g.* MUS81, SLX1/4, GEN1) ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}) ([@bib13]).10.7554/eLife.14709.012Figure 5.Accumulation of Top1cc and reduced homologous recombination in *Atm*^KD/-^ cells.(**A**) Representative In-vitro Complex of Enzymes (ICE) assay (see Materials and method). The top panel was blotted by anti-Topo1 antibody and the bottom panel was probed by p32 labeled total mouse genomic DNA. The amounts of genomic DNA (in μg) loaded on each row are marked on the left. (**B**) Western blot for full length Topo1 on MEFs treated with indicated concentrations of CPT for 2 hr. (**C**) Diagram of replication-dependent (blue shade) and replication-independent (pink shade) Top1cc removal pathways. Top1cc is removed by TDP1 or 3' flapases to generate a single stand gap, which can be repaired by PARP1 and Ligase3-mediated pathways *independent* of replication. In replicating cells, replication forks collide with Top1cc, lead to uncoupling of the leading and the lagging strand, accumulation of single strand DNA (blue dashed box), which promotes fork reversal and eventually a subset of the forks were cleaved. The stalled fork could also be directly converted to breaks (top row, dash arrow). The resulting single-ended DSBs (grey shade circle) can only be repaired by HR (through end resection, homology search and resolution) to generate cross over (CO) (scored as SCEs) or non--crossover. ATM-KD protein selectively inhibits fork breakage in a MRN dependent manner, and could also potentially suppress the same nucleases (Mus81/SLX4) implicated in holiday junction resolution in a later step of HR. (**D**) Representative images and the average (and SEMs) of SCEs per chromosome for vehicle (DMSO) or CPT (1 µM) treated MEFs. Red diamonds point to exchange events. (**E**) Diagram of the DR-GFP reporter, representative FACS plots of the GFP+ cells 48 hr after I-SceI transfection. The bar graphs represent the adjusted GFP%, calculated based on raw GFP% and the I-SceI transfection efficiency. At least two independent ES cell lines per genotype were assayed in \>3 independent experiments. Bar graphs represent the average ± SEMs. In the right panel, the cells were either treated with vehicle (DMSO) or ATMi (15 µM Ku55933) for 36 hr (12 hr after I-SceI transfection).**DOI:** [http://dx.doi.org/10.7554/eLife.14709.012](10.7554/eLife.14709.012)10.7554/eLife.14709.013Figure 5---figure supplement 1.Analyses of immortalized *Atm*^KD/-^ MEFs and Mre11-deficient cells.(**A** and **B**) Two independent In-vitro Complex of Enzymes (ICE) assay results (see Materials and method). The top panel was blot by anti-Topo1 antibody and the bottom panel was probed by P^32^ labeled total mouse genomic DNA. The amounts of genomic DNA (in μg) loaded on each row are marked on the left. The \*\* lanes represents Atm^+/-^ cells treated with 15 μM CPT that were lost during centrifugation due to an equipment error. (**C**) The number of sister chromatid exchange (SCE) per chromosome in *Blm*^+/+^ (WT) or *Blm*^-/-^ cells treated with vehicle (DMSO) or ATMi (15 µM KU55933 for second doubling period) for 24 hr.**DOI:** [http://dx.doi.org/10.7554/eLife.14709.013](10.7554/eLife.14709.013)

In this context, an integrated (at the Pim1 locus) DR-GFP reporter ([@bib42]) revealed a 50% reduction of HR in *Atm*^KD/-^ embryonic stem (ES) cells, but not in *Atm*^-/-^ cells. ATM inhibitor reduced HR in *Atm*^+/+^, but not *Atm*^-/-^ ES cells ([Figure 4D](#fig4){ref-type="fig"}) ([@bib52]; [@bib31]), consistent with potential HR defects. End resection that reveals single strand DNA (ssDNA) and loading of Rad51 protein that is necessary for homology search are two early events required for HR. Yet *IR* induced phosphorylated-RPA (T21) and Rad51 foci, were not significantly compromised in *Atm*^KD/-^ cells ([Figure 6A](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}) ([@bib59]). These findings imply that Atm-KD does NOT block RAD51 loading to resected DSBs and suggest that either a later step of HR is affected in *Atm*^KD/-^ cells or other mechanisms exist to explain the lack of CPT-induced SCEs in *Atm*^KD/-^ cells. In this regard, we found that *CPT*-induced Rad51 foci were markedly decreased in *Atm*^KD/-^ MEFs ([Figure 6B](#fig6){ref-type="fig"}). Moreover CPT-induced DSBs measured by phosphorylated H2AX (γ-H2AX) and the neutral comet assay were also attenuated in *Atm*^KD/-^ cells (but not *Atm*^-/-^ cells) and by ATM kinase inhibitor ([Figure 6C--E](#fig6){ref-type="fig"}). In the same cells, CPT effectively increased alkaline comet tails, an indicator of both single and double stand breaks, in *Atm*^+/-^, *Atm*^-/-^ and *Atm*^KD/-^ cells ([Figure 6F](#fig6){ref-type="fig"}). Together these findings indicate that ATM-KD protein suppressed CPT-induced DSBs formation during replication and thereby reduced SCEs.10.7554/eLife.14709.014Figure 6.ATM-KD blocks CPT-induced double stand breaks formation in replicating cells.(**A**) Representative images and the frequency of cells with \>5 Rad51 foci per cell (Average ± SEMs) at 10 hr after 5 Gy of *IR*. Brca1^SF/SF^ cells homozygous for the S1598F mutation([@bib59]) were used as a control for the lack of Rad51 foci. Scale bar \~10 µm. (**B**) The proportion of cells with \>5 Rad51 foci after *CPT* (0.1 µM, 2 hr) treatment. The bar graph represents the average and SEMs from 3 independent experiments. All p-values in this figure were calculated based on two-tailed student's t-test assuming unequal variances. (**C**) Representative images and quantification of CPT-induced γH2AX foci (0.1 µM, 2 hr). The dot plot represents average and SEMs in three biological replicates with \>200 nuclei per genotype per condition. Scale bar \~10 µm. (**D**) Western blots for pRPA(T21), γH2AX, and total H2AX of cells treated with either Vehicle (−, DMSO) or CPT (+, 0.1 µM) for 2 hr. ATM inhibitor (15 µM, Ku55933) was added 1 hr prior to CPT/vehicle treatment as indicated. (**E**) Quantification of Neutral COMET tail lengths in cells treated with Vehicle (−, DMSO) or CPT (+, 0.1 µM) for 1 hr. The graph represents the average ± SEMs from two independent experiments with over 50 comets quantified for each. (**F**) Quantification of Alkaline COMET tail lengths of cells treated with Vehicle (−, DMSO) or CPT (+, 0.1 µM) for 1 hr. Two replicates of the experiments were performed with over 50 comets quantified for each.**DOI:** [http://dx.doi.org/10.7554/eLife.14709.014](10.7554/eLife.14709.014)10.7554/eLife.14709.015Figure 6---figure supplement 1.Analyses of cell cycle dependent reduction of CPT induced DSBs.(**A**) Proportion of cells with greater than 5 pRPA (pT21) foci 2 hr post 5 Gy IR treatment. (**B**) Representative FACS plots for Bromodeoxyuridine (BrdU) and Propidium Iodide (PI) of ATM^+/-^ MEFs growing at log phase (ctrl), undergoing double thymidine (DT) Block (G1), and cells released into fresh medium for 6 hr after wash-off (S/Release). For DT block, cells were treated for two intervals of 24 hr with 2 mM Thymidine, with a 9 hr wash-off in between with fresh medium. Western blot of whole-cell lysates collected from MEFs treated with indicated concentrations of CPT for 2 hr.**DOI:** [http://dx.doi.org/10.7554/eLife.14709.015](10.7554/eLife.14709.015)

Upon DNA DSBs, Mre11, along with the MRN complex recruits ATM to the DSBs and activates ATM kinase activity. Notably, Mre11 also binds to ssDNA and the affinity of Mre11 to ssDNA is higher than to dsDNA and is independent of DNA ends ([@bib20]; [@bib67]; [@bib47]). Extended ssDNA (potentially without ends) is likely the structure that accumulated at stalled and uncoupled replication forks ([Figure 5C](#fig5){ref-type="fig"}). Correspondingly, recent iPOND experiments have identified MRE11 at the stalled replication fork in vivo ([@bib61]). In this context, we found that ATM kinase inhibitor prevents CPT induced DSBs formation in *Mre11*^+/-^ but not in *Mre11*^-/-^ MEFs. The presence of a nuclease deficient Mre11 (*Mre11*^nuc/-^) that binds and recruits ATM ([@bib9]) is sufficient to abolished CPT induced DSBs in the presence of ATM kinase inhibitor ([Figure 7A](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1A--C](#fig7s1){ref-type="fig"}). Together these findings support a model, in which ATM-KD protein physically blocks CPT induced DSBs formation at replication forks upon recruitment by MRN.10.7554/eLife.14709.016Figure 7.Atm-KD physically blocks the cleavage of CPT-stalled replication fork independent of fork reversal.(**A**) Western blots of *Mre11*^+/-^, *Mre11*^-/-^ or *Mre11*^H129N/-^ (refereed as Nuc/- in the text) MEFs treated with CPT (C, 0.1 µM, 2 hr) or pretreated with ATM kinase inhibitor (CA, ATMi 15 µM, 1 hr, then together with CPT 0.1 µM, 2 hr). (**B**) Visualization and quantification of ssDNA at replication fork junctions in not treated (NT) cells and upon treatment with CPT with and without the ATM inhibitor (15 µM). Statistical analysis t-test according to Mann--Whitney results are \*p≤0.1; \*\*p≤0.01; \*\*\*p≤0.001. (**C**) Representative images and quantification of fork reversal by electron microscopy upon CPT (25 or 100 nM) and CPT+ATMi (Ku55933, 15 µM) treatment. P: parental DNA; D: daughter DNA strands, and R: reversed fork DNA. 70 replication forks were quantified for each genotype at each condition. Statistical analysis *t* test according to Mann--Whitney results are \*p≤0.1; \*\*p≤0.01; \*\*\*p≤0.001. (**D**) Representative images and quantification of the DNA fiber assay. Cells were incubated 30 min with 25 µM IdU, followed by 250 µM of CldU along with either vehicle (DMSO) or CPT (1 µM). The dot plot represents the summary of two independent experiments. \*p\<0.0001.**DOI:** [http://dx.doi.org/10.7554/eLife.14709.016](10.7554/eLife.14709.016)10.7554/eLife.14709.017Figure 7---figure supplement 1.Replication fork analyses in cells treated with CPT.(**A**) *Mre11*^+/C^, *Mre11*^C/-^ and *Mre11*^C/H129N^ immortalized MEFs were stably infected with retrovirus expressing ER-CRE- IRES-hCD2, MACS purified for hCD2+ cells and then induced with 4OHT (200 nM) for 48 hr. PCR confirmed the efficient conversion of the Mre11 conditional allele to the null alleles. PCRs were performed as previously described ([@bib9]). (**B** and **C**) Independent Western blot analyses of *Mre11*^+/-^, *Mre11*^-/-^ or *Mre11*^H129N/-^ MEFs treated with CPT (C, 0.1 µM, 2 hr) or pretreated with ATM kinase inhibitor (CA, ATMi 15 µM, 1 hr, then together with CPT 0.1 µM, 2 hr). (**D**) Western blot analyses of Atm^+/-^, Atm^-/-^ or Atm^KD/-^ MEFs treated with CPT (C, 0.1 µM, 2 hr) or pretreated with Mre11 nuclease inhibitors (CM for Mirin at 500 µM, or CP for PFM01 ([@bib60]) (200 µM, for 1 hr) then with CPT (0.1 µM) together for 2 more hours. (**E**) Western blot analyses of cells treated with Aphidicolin (**A**) or CPT (**C**) or first Aphidicolin for 1 hr, then together with CPT for 2 hrs (AC). (**F**) Representative sensitivity assay to mitomycin C (MMC). (**G**) Western blot analyses of immortalized MEFs treated with CPT (**C**) or CPT and ATM kinase inhibitor (CA) together for 2 hr.**DOI:** [http://dx.doi.org/10.7554/eLife.14709.017](10.7554/eLife.14709.017)

Collision with Top1cc uncouples the progression of the leading and lagging strands, and causes accumulation of ssDNA ([Figure 5C](#fig5){ref-type="fig"}), which were thought to be the precursor of \'fork reversal\' that converts a replication fork into a four-way junction ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) ([@bib73]; [@bib5]). Fork reversal slows replication. In one hand, fork reversal could allow the replication machinery to bypass the lesion using the newly synthesized stand as the template. On the other hand, the four-way junctions, if they persist, could be recognized by structural specific nucleases (*e.g*. MUS81, SLX1/4) implicated in CPT induced DSBs ([@bib53]). In this regard, we reported that CPT induced RPA phosphorylation at Thr 21, a marker for ssDNA and ssDNA induced CHK1 phosphorylation by ATR are normal in *Atm*^KD/-^ cells and ATM kinase inhibitor-treated Atm^+/-^ cells ([Figure 6D](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}, [Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}). Moreover, we found that ATM kinase inhibitor did not alter the frequency or size of CPT induced ssDNA, or the frequency of actual fork reversal in *Atm*^+/-^ cells measured by electron-microscopy ([@bib73])([Figure 7B and C](#fig7){ref-type="fig"}). Correspondingly, CPT significantly reduced fork velocity in *Atm*^KD/-^ as well as control *Atm*^+/+^ or *Atm*^-/-^ cells ([Figure 7D](#fig7){ref-type="fig"}), consistent with fork reversal. We noted that baseline fork progression is slowest in *Atm*^KD/-^ cells ([Figure 7D](#fig7){ref-type="fig"}), potentially reflecting defects in resolving spontaneous Top1cc or related lesions, such as Topo1-processed ribonucleotide mis-incorporation ([@bib35]). Together, our findings support a model, in which ATM is recruited to stalled replication fork by MRE11 (or MRN complex), where ATM kinase activity is necessary to release ATM and allow fork cleavage without affecting fork uncoupling and fork reversal. This role of ATM at the replication fork explains the increased genomic instability, especially chromatid breaks, and hypersensitivity to CPT in murine cells as well as human cancer cells that express catalytically inactive ATM protein.

Discussion {#s3}
==========

*ATM* is a tumor suppressor gene that is frequently inactivated in human cancers. While previous studies have mostly focused on the complete loss of ATM (*Atm*^-/-^, truncating mutations), recent sequencing analyses identified a large number of missense ATM mutations in human cancers with limited information on their biological function. Here we report that cancer-associated ATM missense mutations are highly enriched in the kinase domain. Using murine models, we showed that expression of ATM-KD causes cancer more frequently and rapidly than loss of ATM, and the *Atm*^KD/-^ cancers are selectively hypersensitive to Topo1 inhibitors. As such, Topo1 inhibitors could potentially be a *targeted* therapy for tumors with ATM kinase domain mutations. Mechanistically, we found that ATM-KD physically blocks CPT-induced DSBs formation during replication in a MRN-dependent manner. Given that both *Atm*^KD/-^ cells and ATM kinase inhibitor treated *Atm*^+/-^ cells display defects in replication-dependent Top1cc removal, our data revealed not only a neomorphic function associated with kinase domain point mutations of ATM, but also a previously unappreciated auto-phosphorylation dependent structural function of normal ATM that is not apparent in *Atm*^-/-^ cells (due to the lack of both ATM protein and ATM kinase activity). This new function of ATM expands the repertoire through which ATM functions as a tumor suppressor and has implications on DNA repair and cancer therapy.

Despite the \~two fold increased breast cancer risk in heterozygous ATM mutation carriers ([@bib55]; [@bib55][@bib1]) and 1--2% carrier rate in Caucasians, truncating ATM mutations are exceedingly rare (\<1/400, in contrast to the predicted 8%) in early-onset breast cancers patients ([@bib25]). This and other findings ([@bib62]) led to the speculation that ATM mutations are different in cancer compared to A-T ([@bib27]). Here we reported that, while *Atm*^+(C)/KD^ mice are normal ([@bib71]), somatic inactivation of the *Atm*^C^ allele in VKD mice led to aggressive lymphomas. As such, while missense ATM mutations in the kinase domain are not compatible with embryonic development when homozygous and are not found in A-T, they could predispose carriers to cancers, and maybe have more potent oncogenic potential than A-T causing truncating mutations. Notably, loss of ATM preferentially affects NHEJ ([@bib26]) and predisposes patients primarily to lymphomas. Here we show that *Atm*^KD^ also compromises HR, a pathway implicated in breast, ovarian, pancreatic and prostate cancers, in which recurrent ATM missense mutations were recently identified ([@bib56]; [@bib16]). MRE11 binds to ssDNA independent of DNA ends in vitro ([@bib20]; [@bib67]; [@bib47]) and MRE11 has been identified at stalled replication forks *in vivo* ([@bib61]). Our results also revealed that the ATM-KD protein physically blocks strand cleavage in a MRN-dependent manner, further suggesting the level of mutant ATM protein and MRN status can modify both the cancer risk and therapeutic responses. ATM kinase inhibitor seems to reduce CPT-induced DSBs more efficiently in *Mre11*^Nuc/-^ cells, than in *Mre*^+/-^ cells ([Figure 7A](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1A--C](#fig7s1){ref-type="fig"}). This result suggests that Mre11 nuclease activity might contribute to the removal of ATM or the termination of ATM activation. Further investigation is likely needed to clarify this issue. We noted that loss of sae2, a modulator of Mre11 nuclease activity in yeast, causes persistent DNA damage responses mediated by *tel1/mec1*, yeast orthologs of *ATM* and *ATR*. Two recent studies have identified mre11 mutations that rescued the hyper activation of mec1 in sae2 deficient yeast. ([@bib14]; [@bib51]). Mre11 nuclease might also contribute to fork cleavage directly. In this context, we noted that Mre11 nuclease inhibitors -- either PFM01 or Mirin ([@bib60]), reduced CPT induced γ-H2AX in both *Atm*^+/-^ and *Atm*^-/-^ cells, supporting an ATM independent function of Mre11 in fork cleavage ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}). However, given the toxicity associated with Mre11 nuclease inhibitors, further experiments are warranted to understand the molecular details of MRE11 function in fork cleavage. Together, these findings support our model in which MRE11, together with the MRN complex recruits ATM to the stalled replication forks, while the kinase activity of ATM is important for fork cleavage in the presence of ATM protein.

The mechanism identified here also suggests that *Atm*^KD/-^ tumors should be hyper-sensitive to agents targeting genes involved in Top1cc removal/repair (*e.g.* PARPs,TDP1) ([@bib50]; [@bib43]) andgenotoxic agents that require similar \'strand-cleavage\' mechanisms for repair (*e.g.* crosslink agents --like Mitomycin C) ([@bib78]). Consistent with these predictions, *Atm*^KD/-^ T cells are hypersensitive to PARP inhibitor alone or in combination with CPT ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}) and *Atm*^KD/-^, but not *Atm*^-/-^ MEFs, are hypersensitive to Mitomycin C ([Figure 7---figure supplement 1F](#fig7s1){ref-type="fig"}). Together, these findings further expand the therapeutic options for ATM mutated cancers. The similarity between *Atm*^KD/-^ cells and ATM kinase inhibitor treated *Atm*^+/-(+)^ cells further suggest that ATM inhibitors, which have recently entered clinical trials, could potentially increase the efficacy of Topo1 inhibitors in *ATM*^+/+^ cancers. Finally, the lack of CPT-induced γ-H2AX described for *Atm*^KD/-^ cells could be used as a biomarker to assess the function of ATM mutations, including the potential confounding MRN status.

While the lack of CPT-induced DSBs might explain the lack of CPT-induced Rad51 foci and SCEs in *Atm*^-/KD^ cells, the reason for which I-SceI nuclease induced \'clean\' DSBs could not be efficiently repaired by HR in the *Atm*^KD/-^ cells is not apparent. The efficient accumulation of IR induced Rad51 foci in *Atm*^-/KD^ cells, suggests that Atm-KD does not block the loading of Rad51 to resected DSBs, an early step required for HR ([Figure 6](#fig6){ref-type="fig"}). However, Rad51 loading or filament stability at a stalled replication fork might also be regulated differently from those at resected DSBs (from IR) and might occur independent of DSBs ([@bib58]). In any case, our findings suggest that ATM-KD probably suppresses a later step of HR, especially holiday junction resolution, because the same structure specific nucleases (MUS81 and SLX1/4), are implicated in both holiday junction resolution and strand cleavage during Interstrand Crosslink (ICL) or Top1cc repair ([@bib78]; [@bib57]). The lack of MUS81 or SLX1/4 function could explain both the HR defects and the Top1cc removal defects in *Atm*^-/KD^ cells. Accordingly, we found that *Slx4*^-/-^ and, to a lesser extent *Mus81*^-/-^, MEFs also display reduced numbers of CPT-induced DSBs ([Figure 7---figure supplement 1G](#fig7s1){ref-type="fig"}). In addition, the slow replication fork progression in *Atm*^-/KD^ cells ([Figure 7D](#fig7){ref-type="fig"}) might also indirectly reduce HR efficiency measured by DR-GFP.

Intermolecular autophosphorylation is a common feature of ATM, DNA-PKcs and ATR ([@bib40]; [@bib22]; [@bib30]; [@bib3]). We previously reported that DNA-PKcs recruited by Ku to DSBs block NHEJ in the absence of autophosphorylation ([@bib30]). Here, ATM-KD recruited by MRE11 blocks replication fork cleavage upon collision with Top1cc in a remarkably similar manner, suggesting that autophosphorylation of PIKKs might have a common function in promoting their release from their respective activation partners (Ku for DNA-PKcs, MRN for ATM) and license distinct repair events (NHEJ for DNA-PKcs, strand cleavage for ATM). In the *Atm*^KD/-^ cells, the defects in Top1cc removal combined with the lack of ATM kinase activity-mediated DNA damage response leads to severe genomic instability, embryonic lethality, and enhanced oncogenic potential.

Materials and methods {#s4}
=====================

Genomic analyses of ATM mutations {#s4-1}
---------------------------------

ATM somatic mutations were collected from 5,402 cancer patients from 24 tumor types in TCGA, including ACC, BRCA, CHOL, COADREAD, ESCA, HNSC, KIRC, LAML, LIHC, MESO, PAAD, PRAD, SARC, STAD, THYM, UCS, BLCA, CESC, COAD, DLBC, GBM, KICH, KIRP, LGG, LUAD, OV, PCPG, READ, SKCM, TGCT, UCEC, and UVM. All maf files of those tumor types were downloaded using firehose (<http://gdac.broadinstitute.org>). To unify the annotation format, we first used the liftover tool (<https://genome.ucsc.edu/cgi-bin/hgLiftOver>) to map all coordinates to hg19, and then re-annotated variant effect with VEP (<http://www.ensembl.org/info/docs/tools/vep/>) under transcript NM_000051.3. Mutation types Missense_Mutation, In_Frame_Del, and In_Frame_Ins were classified as missense, while Nonsense_Mutation, Frame_Shift_Del, Frame_Shift_Ins, and Splice_Site were classified as truncating mutations. Germline ATM mutations are from A-T patients in the Leiden open variable database LOVD2 (<http://chromium.lovd.nl/LOVD2/home.php?select_db=ATM>). Protein mutation position was curated and annotated based on the mutation effect provide by LOVD2. Start_Codon, Frame_Shift_Del, Large_DEL, Nonsense_Mutation, Frame_Shift_Ins, Splice_Site, and Stop_Codon are labeled as Truncating in our analysis.

Mutation density estimation {#s4-2}
---------------------------

To measure the mutation density of different ATM positions, we applied a Gaussian kernel smoother to smooth the number of mutations of each amino acid site. If we use $y\left( x_{i} \right)(i = 1,2,~\cdots,~n)$ to represents the number of mutations in each site $x_{i}$, then the Gaussian kernel smoother of $y\left( x \right)$ is defined by:$$\hat{y}\left( x_{i} \right) = \frac{\sum_{j = 1}^{n}K(x_{i},x_{j})y(x_{j})}{\sum_{j = 1}^{n}K(x_{i},x_{j})}$$

where $K\left( {x_{i},x_{j}} \right) = \text{exp}\left( {- \frac{{(x_{i} - x_{j})}^{2}}{2b^{2}}} \right)$ is the Gaussian kernel, and $b$ indicates the window size (we use 80 in the current study). Missense mutations and truncating mutations were separately considered. To estimate the expected number of mutations in ATM, we assume the ratio between silent and non-silent mutation (e.g. missense mutation) is constant, and then the frequency, as well as its confidence interval, to observe a missense mutation can be estimated by fitting a binomial distribution with $n$ trials. The shadowed curve is the 95% confidence interval of fold change between observation and expectation after a Bonferroni Correction. The supplementary table 1 shows the result of the permutation analyses for the expected and observed mutations in ATM or ATM kinase domain (AA2711-2962, [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}).

Structure simulation analyses {#s4-3}
-----------------------------

Homology model of human ATM was generated based on the crystal structure of human mTOR(PDB 4JSP) ([@bib72]) using the ROBETTA server, setting default parameters ([@bib34]; [@bib2]). Briefly, the AAs 2520--3056 of human ATM was submitted to the ROBETTA server and the mTOR crystal structure was identified as a template. After aligning the query sequence with the parent structure, a template was generated and the variable regions were modelled in the context of the fixed template using Rosetta fragment assembly. Finally, the model was subjected to several rounds of optimization by Rosetta's relax protocol. All structure analyses and visualizations were performed with pymol (<http://pymol.org/>).

Human cancer cell lines {#s4-4}
-----------------------

Human cancer cell lines -- BT-474 (Breast cancer), Granta519 (MCL), HEC251 (Endometrium tumor) and SNU283 (Colon Cancer) were selected, since the CCLE (Broad Institute) have identified mis-sense mutations in or around the ATM kinase domains in these cell lines. We have verified the identity of these cell lines to the best of our knowledge -- based on ATM mutation status, ATM expression and activities ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). HBL2 cell lines were selected as the MCL control, since similar to Granta519, HBL2 has deregulated expression of CyclinD1 and is WT for ATM. Other cell lines (Hela and U2OS) were also validated for normal expression of ATM and ATM kinase activity. None of the used cell lines were in the list of commonly misidentified cell lines maintained by the International Cell Line Authentication Committee (2016 May version).

Mouse alleles and in vivo lymphocyte analyses {#s4-5}
---------------------------------------------

All the mouse alleles used have been previously described ([@bib71]; [@bib19]; [@bib77]; [@bib21]), *Atm*^C^, *Atm*^KD^, *VavCre*^+^, *Rosa*^ERCre^. All the animal work was approved by and performed according to the regulations of the Institutional Animal Care and Use Committee (IACUC) of Columbia University. For development analyses, VN, VKD and littermate matched control mice were euthanized at 4--6 weeks of age. Total lymphocyte counts, flow cytometry analyses and in vitro class switch recombination were performed as described previously ([@bib39]). Briefly, splenic B and T-cells were isolated using Magnetic-Activated Cell Sorting (MACS) for CD43^-^ and CD43^+^ fractions, respectively, following the manufacturer's protocol (Miltenyi Biotec). B-cells (CD43^-^) were stimulated with LPS (20 µg/ml) and IL-4 (20 ng/ml) for 4.5 days at a cellular concentration no more than 1 × 10^6^ cells/ml, and the T-cells (CD43^+^) were activated by Con A (2 µg/ml) for 3.5 days ([@bib39]). Metaphases were collected at the end of the cytokine stimulation period after 4 hr of colcemid (100 ng/ml KaryoMax, Gibco) treatment, and stained with Telomere FISH probes as previously described ([@bib71]; [@bib26]). Lymphoma- bearing animals were identified based on enlarged lymph nodes (B cell lymphomas) or severely hunched postures (thymic lymphomas) and analyzed. For the tumor studies, the investigators were not blinded.

Mouse embryonic fibroblast (MEF) {#s4-6}
--------------------------------

MEFs were harvested at embryonic day 14.5 (E14.5) based on timed breeding and immortalized using retrovirus expression of the large and small SV40 T antigen. Immortalized culture was established after three passages (1:3 dilutions) after the primary infection. To induce 4-hydroxytamoxifen (4OHT) dependent nuclear translocation of ER-Cre recombinase ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}), the cells were plated at low density (\~30% confluence), and passed three times (48 hr interval) in the presence of 4OHT (200 nM). Complete deletion of the conditional allele was confirmed using PCR as described previously ([@bib71]). For drug sensitivity assays, the immortalized MEF treated for 4OHT (3 rounds) were seeded in gelatinized 96-well plates (6 × 10^3^/well). Twenty-four hours after the initial seeding, the cells were treated with the compounds at indicated concentrations for 48 hr. The cell number was quantified using CyQuant (Molecular Probes), a nucleotide stain, per the manufacturer's instructions. The relative survival was calculated relative to the cell number in the untreated wells.

Immunofluorescence and quantification of repair protein foci {#s4-7}
------------------------------------------------------------

Immunofluorescence was performed on 4% formaldehyde/PBS fixed, 1% Triton-X/PBS treated cells using the following antibodies: Rad51 (Clone PC130, 1:200, Calbiochem) phospho-RPA pT21 (Cat. \# ab109394, 1:500, Cell Signaling) γH2AX (Cat. \#07--164, 1:500, EMD Millipore), and CyclinA2 (Clone CY-A1, 1:500, Sigma-Aldrich). Slides were scanned on the Carl Zeiss Axio Imager Z2 equipped with a CoolCube1 camera (Carl Zeiss, Thornwood, NY). Metafer 4 software (MetaSystems, Newton, MA) was used for automated quantification of Rad51, pRPA, γH2AX foci. More than 500 cells were quantified for every experimental replicate. Images were exported and processed on ISIS software (MetaSystems).

Western and southern blotting {#s4-8}
-----------------------------

The following antibodies were used for Western blots on whole cell lysate: ATM (clone MAT3, 1:5000), β-Actin (clone A5316, 1:20,000) and Vinculin (clone V284, 1:10,000) from Sigma-Aldrich; phospho-Kap1 (Cat. \#A300-767A, 1:1000) and Top-I (Cat. \# A302-590, 1:1000) from Bethyl laboratory; phospho-RPA pT21 (Cat. \# ab109394, 1:5000) from Abcam; RPA (clone RPA30, 1:5000), γH2AX (Cat. \#07--164, 1:1000) and H2AX (Cat. \#07--627, 1:1000) from EMD Millipore; phospho-Chk1 (clone 133D3, 1:500), Mre11 (Cat. \#4895S, 1:1000), Kap1/TIF1β (clone C42G12, 1:1000), and Pten (clone D4.3 XP, 1:1000) from Cell Signaling and PCNA (clone PC10, 1:1000) from Santa Cruz. To confirm deletion of the ATM conditional allele in VKD and VN mouse models, Southern blot was performed on KpnI digested genomic DNA and probed with the ATMCKO 3' probe ([@bib77]). For clonal analyses of the thymic lymphomas or the B cell lymphomas, Southern blot was performed on EcoRI-digested genomic DNA, and blotted with Jβ1.6, Jβ2.7 probes ([@bib77]; [@bib33]) or Jh4 and myc-A probe ([@bib28]).

Sister chromatid exchange assay {#s4-9}
-------------------------------

Cells were incubated for two doubling times (48 hrs) with Bromodeoxyuridine (BrdU, Sigma-Aldrich, 5 µg/ml). During the second doubling period (hours 25--48), the cells were also incubated with either vehicle (DMSO) or CPT (1 µM). BrdU-incorporated sister chromatids were quenched using Hoechst33258 (50 µg/ml) treatment followed by UV exposure, then stained with DAPI (Vectashield). Slides were scanned for metaphase spreads using the Carl Zeiss Axio Imager Z2 equipped with a CoolCube1 camera (Carl Zeiss, Thornwood, NY) and Metafer 4 software (MetaSystems, Newton, MA). Spreads were quantified and images exported via ISIS software (MetaSystems). Over 40 metaphases were quantified for each genotype. A total of three independent replicates were performed.

COMET assay {#s4-10}
-----------

Neutral and alkaline COMET assays were performed per manufacturer's protocol (Trevigen, Gaithersburg, MD). Slides were scanned for COMETs using Metafer 4 and tail lengths quantified using ISIS.

In-vitro complex of enzymes (ICE) assay {#s4-11}
---------------------------------------

Covalent complexes of TopI-DNA were detected as previously described ([@bib45]). Briefly, cells were gently lysed in 1% Sarkosyl/TE solution, ultracentrifuged through a CsCl~2~ gradient (6 M) and the resulted genomic DNA was dissolved in TE. Equivalent amounts of DNA were loaded on 0.45 µm Nitrocellulose membranes, and probed for Top-1 (Cat. \# A302-590, 1:1000, Bethyl). Loading controls were probed with radiolabeled total mouse genomic DNA.

DNA fiber assay {#s4-12}
---------------

Cells were first incubated with 25 µM IdU (30 min) then with additional 250 µM CldU (Sigma), trypsinized and harvested in ice-cold 1 x PBS, lysed using 1% SDS/Tris-EDTA and stretched along glass coverslips. Slides were stained using primary Anti-IdU (B44, BD Biosciences), CldU (BU1/75 (ICR1), Abcam) antibodies and corresponding secondary anti-Rat Alexa594, and anti-mouse Alexa488 (Molecular Probes) antibodies. DNA fibers were analyzed on the Nikon Eclipse 80i microscope equipped with remote focus accessory and CoolSNAP HQ camera unit using the 60 x /1.30 NA oil Plan Fluor lens. All images were processed and quantified with NIS-Elements AR. Lengths of fibers were calculated with a base pair length of 3.4 Å (340 pm).

Comparative genomic hybridization (CGH) assay {#s4-13}
---------------------------------------------

1 µg of differentially labeled genomic DNA from tumor and non-tumor control (kidney) derived from the same animal were hybridized on the 244 k Mouse Genome CGH microarray platform (Agilent) and analyzed on Agilent Genomic Workbench and Microsoft Excel as previously described ([@bib74]; [@bib70]).

Electronmicroscopic (EM) analyses of genomic DNA {#s4-14}
------------------------------------------------

In vivo psoralen cross-linking, isolation of genomic DNA from mammalian cells, enrichment of replication intermediates, and analysis of data was performed as previously described ([@bib44]; [@bib65]). Briefly, 5--10 × 10^6^ Mouse Embryonic Fibroblasts (Rosa^+/ERCRE^ Atm^+/C^) cells were harvested and genomic DNA was cross-linked by three rounds of incubation in 10 µg/ml 4,5′,8-trimethylpsoralen (Sigma-Aldrich) and 3 min of irradiation with 366 nm UV light on a precooled metal block. Cells were lysed and cellular proteins were digested with 2 mg proteinase K (Life technologies) in 5 ml digestion buffer. DNA was purified by isopropanol precipitation, restriction digested with PvuII HF for 4 hr at 37°C, and replication intermediates were enriched using benzolylated naphthoylated DEAE-cellulose (Sigma--Aldrich) in 3 ml BioRad poly-prep chromatography columns. Samples were prepared by spreading DNA on carbon-coated grids in the presence of benzyl-dimethyl-alkylammonium chloride and formamide. Rotary platinum shadowing was performed using the Balzers BAF400 with Quartz crystal thin film monitor. Images were acquired on a JOEL 1200 EX transmission electron microscope with side-mounted camera (AMTXR41 supported by AMT software v601) and analyzed with ImageJ (National Institutes of Health).

In vivo isogenic Leukemia and irinotecan treatment (diagrammed in [Figure 4A](#fig4){ref-type="fig"}) {#s4-15}
-----------------------------------------------------------------------------------------------------

To determine the therapeutic effect of clinically used Topo1 inhibitor -- irinotecan in vivo, we generated isogenic leukemia by transducing bone marrow from Rosa^+/CreERT2 ^Atm^C/KD^ mice treated with 5-Fluorouracil (5-FU) were transduced with retrovirus encoding activated Notch1 (ΔE-Notch1) and GFP(MSCV-ΔENOTCH-IRES-GFP) ([@bib66]) and transplanted into semi-lethal irradiated (8.5 Gy) recipient mice (n = 3). Once the leukemia developed (monitored by peripheral blood GFP+ cells), \~1 × 10\^6 GFP+ leukemia cells (from one mouse to ensure clonality) were transduced to 2nd recipients (n = 4--6). 4 days later, the 2nd recipients were fed with oral tamoxifen (n = 3) or carrier alone (sun flower oil, n = 3) for two days. When the 2nd recipients developed leukemia, the leukemia cells were genotyped for ATM status (KD/- or KD/C) and analyzed for clonality (TCRβ rearrangements by Southern). Once the isogenic (defined by identical TCRβ rearrangements) leukemia was obtained, they were transduced to tertiary recipients (n = 5--10 per genotype). 3 days after the transplantation, the tertiary recipients were treated with IP injection of irinotecan (10 mg/kg) for 5 days or vehicle alone (for 5 days) and observed for leukemia development. In \~10 days after the last drug injection, the vehicle groups displayed terminal diseases and both the vehicle control and the irinotecan treated mice were euthanized and analyzed for GFP+ cells in the spleen, histology and spleen weight and size. Similar experiments were performed on *Rosa*^+/CreERT2 ^*Atm*^C/C^ bone marrow derived, isogenic *Atm*^C/C^ vs *Atm*^-/-^ Notch driven leukemia and representative results are shown in [Figure 4---figure supplement 1C--F](#fig4s1){ref-type="fig"}.
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10.7554/eLife.14709.018

###### Nonsynonymous mutations reported for A-T patients (A) in the Leiden open variable database (<http://chromium.lovd.nl/LOVD2/home.php?select_db=ATM>) or The Cancer Genome Atlas (TCGA) at the time of primary analyses (5402 cases, (B).

At the time of primary analyses, 2 TCGA cancer cases (1 and 2 in the table below) have mutations involving N2875 of human ATM. Among them, the first case also has \'shallow del\' in ATM region, consistent with Mut/- genotype. Since then, one additional prostate cancer (case 3) was reported to have N2875S mutations. While ATM region deemed \'diploid\', the allele frequency of the N2875S allele is 0.92 (92% of the reads in this region are mutated), consistent with phenotypically - homozygous status. 1) TCGA-EW-A1J6-01 breast cancer N2875S shallow del; 2) TCGA-G9-7521-01 prostate cancer N2875K diploid; 3) TCGA-YL-A8S9-01 prostate cancer N2875S diploid; allele freq = 0.92.

**DOI:** [http://dx.doi.org/10.7554/eLife.14709.018](10.7554/eLife.14709.018)
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Decision letter

Walter

Johannes

Reviewing editor

Harvard Medical School

,

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors\" for consideration by *eLife*. Your article has been favorably evaluated by Charles Sawyers (Senior editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

In previous studies these authors made the rather surprising finding that while mice deficient in ATM are viable, mice that express a kinase dead version of ATM exhibit early embryonic lethality. This suggests that the loss of ATM and expression of a kinase dead version of ATM leads to very different cellular defects. In this manuscript they explore the potential function of ATM mutations in cancer. They find that there is an increase in cancers with mutations that would be expected to lead to the generation of a kinase-dead version of ATM, suggesting that this mutation may promote cancer. They show that the expression of a kinase dead version of ATM, but not loss of ATM, prevents the removal of Topo-isomerase I-DNA adducts making these tumor cells more sensitive to Topo-isomerase inhibitors. Overall the experiments are well done and the findings shed important light on the potential unique activity of the kinase dead version of ATM. Moreover, they are relevant to the treatment of cancers with ATM mutations that effect kinase activity.

The following issues must be addressed before publication:

Main Points:

1\) Given that the effects on CPT-induced DSB formation are not observed in ATM null cells, it appears that the effects in KD mutants represent a dominant negative effect and not a normal function of ATM in the response to DSBs. Therefore, the claim that they have identified a new function of ATM is not valid.

2\) The identification of N2875K mutation, which is embryonic lethal in a mouse in the absence of wild-type ATM, in two human tumors in the TCGA is potentially important. But the authors need to specify if the N2875K in the human tumors was homozygous or additionally associated with loss of chromosome 11q23. The selective sensitivity of ATM kinase dead human cancer cell lines to camptothecin could be demonstrated by knockout of the kinase dead protein. This would considerably strengthen this experiment with the human cancer cell lines.

3\) In [Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"} and [Figure 5B](#fig5){ref-type="fig"} pRPA32(T21) was used to show in all genotypes, ssDNA formation was not significantly affected upon CPT treatment (Western blot); however, number of Rad51 foci was significantly reduced in *ATM^KD/-^*cells. The authors attributed this phenotype to lack of DSBs in *ATM^KD/-^*cells. Another explanation would be defect in Rad51 loading in *ATM^KD/-^*cells assuming equivalent amount of ssDNA is present in all cells. While reduce number of DSBs might explain why Rad51 foci decreased in *ATM^KD/-^*cells, how does it explain equivalent levels of ssDNA in all three genotypes? The authors should include a more detailed discussion.

4\) In [Figure 5D](#fig5){ref-type="fig"}, it was shown that ATM-KD protein blocks CPT-induced DSB formation in MRN-dependent manner. The authors concluded that MRN (with nuclease active or inactive MRE11) recruited *ATMKD* to DNA and ATM-KD protein blocks the conversion of Top1cc lesion to DSBs. However, for this to occur, MRN has to recognize Top1-induced SSBs first in order to recruit ATM. Have there been reports that MRN recognizes and binds to SSBs?

5\) In the same figure, it looks like upon CPT treatment, ATM inhibitor in cells expressing nuclease-deficient MRE11 abolished gH2AX formation (indicative of DSB generation) while in wild type MRE11-expressing cells only partially reduced gH2AX. Is the difference reproducible? If so, this would suggest that MRE11 nuclease also contribute gH2AX (DSB) formation in CPT-treated *ATM^KD/-^*cells (again, if MRN binds to SSB). What is the likely explanation?

Other Specific Issues (in no particular order):

1\) The graph in [Figure 2D](#fig2){ref-type="fig"} indicates that the incidence of Thymic lymphoma is about 65%, not 75% as indicated in the text. The difference between the VN and VKD animals is now not very different. Also, were tests for statistical significance performed on all these comparisons?

2\) To be convincing, rather than showing four examples, the spleen weight of appropriate numbers of mice should be reported for [Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}.

3\) The results in [Figure 4A](#fig4){ref-type="fig"} (particularly the comparison with *Atm^-/-^*) need to be quantified in multiple experiments to be convincing.

4\) Why is there no effective suppression of CPT-induced DSB formation in the *Mre11^+/-^* cells in [Figure 5D](#fig5){ref-type="fig"}?

5\) The ATM kinase dead mutation generated by Canman et al. contained two missense mutations, not a single N2875K mutation.

6\) The nomenclature for the mice needs to be clarified in the Abstract and Introduction. The meaning of *Atm^C^* is not clear in the Abstract.

7\) There are grammatical errors that should be corrected.

8\) Work by Katyal S et al. (published in 2014 on Nature Neuroscience), which was referenced by the authors, showed that ATM depletion inflicted more DNA damage upon CPT treatment than inhibition of ATM kinase activity in quiescent astrocyte. However, the authors reported here that *Atm^KD/-^*cells are more sensitive to CPT than *Atm^-/-^* cells. What may contribute to this difference? Cell type, cell cycle (proliferating vs. quiescent) or others.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Charles Sawyers (Senior editor), a Reviewing editor, and two reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

First, in the current [Figure 7A](#fig7){ref-type="fig"}, the authors showed that Mre11 nuclease activity (*Mre11^+/-^)* contributes to CPT-induced DSB generation in the presence of ATM-KD protein. Two additional biological replicates were provided in [Figure 7---figure supplement 1B and 1C](#fig7s1){ref-type="fig"}. However, the data presented in the supplemental figures are not convincing -- there is no more gH2AX in *Mre11^+/-^* than in *Mre11*^H129N/-^. There is a very little gH2AX induction in these two additional experiments, compared to [Figure 7A](#fig7){ref-type="fig"}. Therefore, it is not straightforward to conclude whether the nuclease activity of Mre11 also contribute to CPT-induced DSB generation in this context. The author should re-phase accordingly.

The second point regards the lack of RAD51 foci in *ATM^KD^* cells treated with CPT. The authors attributed this observation to the lack of DSB generation *ATM^KD^* cells, rather than impaired RAD51 loading. While this statement is valid with the support the absence (or reduced number) of gH2AX foci and neutral comet assay, the possibility of defective RAD51 loading should not be excluded. The authors stated in the response to reviewer\'s comment that the ssDNA at stalled replication fork would not lead to RAD51 loading. However, two independent studies have directly or indirectly shown that RAD51 is present at stalled replication forks to promote fork reversal or protect the integrity of nascent DNA strands (Zellweger R et al., JCB, 2015 and Schlacher K et al., Cell, 2011). The later study actually proposed that the stability of RAD51 filament, rather than RAD51 \"loading\", is important for protecting nascent DNA at stalled fork. Whether RAD51 loading is an issue or not does not affect the core value of this manuscript, but it would be nice if the authors could make a minor revision to include all possibilities.

10.7554/eLife.14709.020

Author response

*The following issues must be addressed before publication:*

*Main Points:*

1\) Given that the effects on CPT-induced DSB formation are not observed in ATM null cells, it appears that the effects in KD mutants represent a dominant negative effect and not a normal function of ATM in the response to DSBs. Therefore, the claim that they have identified a new function of ATM is not valid.

We would like to thank the reviewer for pointing this out. We now stated in the Discussion (first paragraph) as we identified a potential "neomorphic" oncogenic function of kinase-dead ATM protein. We also noted that, given our results from both *Atm~KD/-~*cells and ATM kinase inhibitor treated cells, suggests that both ATM-KD and the "normal" ATM protein are recruited to CPT induced stalked replication forks by an MRE11-dependent mechanism (see response to point 4 for Mre11 binding specificities). And in this context, ATM kinase activity and potentially the inter-molecular auto-phosphorylation, are necessary to release ATM, which in turn allows fork cleavage. As such, our ATM-KD model likely reveals a phosphorylation dependent structural function of normal ATM protein that is not apparent in the ATM null mouse/cells (lacking both ATM protein and its kinase activity). We have now clarified this point in the first paragraph of the Discussion.

2\) The identification of N2875K mutation, which is embryonic lethal in a mouse in the absence of wild-type ATM, in two human tumors in the TCGA is potentially important. But the authors need to specify if the N2875K in the human tumors was homozygous or additionally associated with loss of chromosome 11q23. The selective sensitivity of ATM kinase dead human cancer cell lines to camptothecin could be demonstrated by knockout of the kinase dead protein. This would considerably strengthen this experiment with the human cancer cell lines.

At the time of primary submission, 2 TCGA cancer cases (1 and 2 in the table below) have mutations involving N2875. Among them, the first case also has "shallow del" in ATM region, consistent with Mut/- genotype. Since then, one additional prostate cancer (case 3) was reported to have N2875S mutations. While ATM region deemed "diploid", the allele frequency of the N2875S allele is 0.92 (92% of the reads in this region are mutated), consistent with phenotypically -- homozygous status (Results and [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}).

1\) TCGA-EW-A1J6-01breast cancerN2875Sshallow del;2) TCGA-G9-7521-01prostate cancerN2875Kdiploid;3) TCGA-YL-A8S9-01prostate cancerN2875Sdiploidallele freq= 0.92;

To address whether the hypersensitivity to CPT in human cancer cell lines expressing catalytically inactive ATM depending on the expression of ATM protein, we used shRNA to knockdown ATM in ATM mutated Granta519 cells, a human mantle cell lymphoma (MCL) cell line, and a control ATM WT MCL cell line -- HBL2. While knockdown of ATM in HBL2 did not significant alter the CPT sensitivity, knockdown of mutated ATM in Granta519 cells moderately yet significantly reduced CPT sensitivity (new [Figure 3E](#fig3){ref-type="fig"}). Moreover, we showed that the CPT hyper-sensitivity in Granta519 cells is associated with increased apoptosis (measured by PI staining) and shRNA knockdown of the mutated ATM led to statistic significant decrease of CPT (5nM 48hr) induced apoptosis in Granta519 cells without significant changes in the baseline (without CPT) apoptosis cell percentage (New [Figure 3---figure supplement Figure 1C and 1D](#fig3s1){ref-type="fig"}).

3\) In [Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"} and [Figure 5B](#fig5){ref-type="fig"} pRPA32(T21) was used to show in all genotypes, ssDNA formation was not significantly affected upon CPT treatment (Western blot); however, number of Rad51 foci was significantly reduced in ATM^KD/-^cells. The authors attributed this phenotype to lack of DSBs in ATM^KD/-^ cells. Another explanation would be defect in Rad51 loading in ATM^KD/-^cells assuming equivalent amount of ssDNA is present in all cells. While reduce number of DSBs might explain why Rad51 foci decreased in ATM^KD/-^ cells, how does it explain equivalent levels of ssDNA in all three genotypes? The authors should include a more detailed discussion.

We noted that "IR" induced Rad51 foci formation (Now [Figure 6A](#fig6){ref-type="fig"} (previously [Figure 4E](#fig4){ref-type="fig"})) are not statistically reduced in *Atm~KD/-~*cells, in contrast to the severe reduction IR induced Rad 51 foci in BRCA1 mutant cells with known Rad51 loading defects. Together with the reduced CPT induced Rad51 foci, these data indicate that ATM-KD protein does *not* block RAD51 loading from clean DSBs or RPA coated single strand DNAs. We have now clarified this in the Results (subsection "ATM-KD blocks replication-dependent removal of Topo-isomerase I DNA adducts at the step of strand cleavage" second paragraph).

In the event of "stalled replication", RPA coated ssDNA (marked by phosphorylated RPA) can accumulate due to the un-coupling of the leading and lagging strands, as diagrammed in [Figure 5C](#fig5){ref-type="fig"} (blue dashed box), observed in electron-microscopy (EM) experiments in [Figure 7B](#fig7){ref-type="fig"}. This accumulation of single stand DNA at the stalled replication forks were thought to be the precursor for fork reversion and could be generated before DSBs and would NOT lead to Rad51 loading. This is distinct to from the pRPA bounded ssDNA originated from resected DSBs. We note, upon CPT treatment, *Atm~KD/-~*cells (or Atm kinase inhibitor treated cells) accumulates normal levels of pRPA (measured by Western Blotting, [Figure 6D](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}), single strand DNA at the fork (by EM, [Figure 7B](#fig7){ref-type="fig"}), fork reversal products (by EM, [Figure 7C](#fig7){ref-type="fig"}) and delay in replication fork progression (by DNA fiber assay, [Figure 7D](#fig7){ref-type="fig"}), together those data support that Atm-KD does *not* block fork-uncoupling or fork reversal.

Given the robust levels of IR induced RAD51 foci in *Atm~KD/-~* cells and the lack of CPT induced RAD51 foci, our results are most consistent with the lack of CPT induced DSBs due to strand cleavage defects.

This is further supported by the lack of CPT induced g-H2AX and neutral comet tails. We have now moved the diagram from supplementary Figure to [Figure 5C](#fig5){ref-type="fig"} to better elucidate our working model and complex structures at stalled replication forks. We also expanded the Results and discussions to better explain our rationales and our working model (subsection "ATM-KD blocks replication-dependent removal of Topo-isomerase I DNA adducts at the step of strand cleavage").

4\) In [Figure 5D](#fig5){ref-type="fig"}, it was shown that ATM-KD protein blocks CPT-induced DSB formation in MRN-dependent manner. The authors concluded that MRN (with nuclease active or inactive MRE11) recruited ATMKD to DNA and ATM-KD protein blocks the conversion of Top1cc lesion to DSBs. However, for this to occur, MRN has to recognize Top1-induced SSBs first in order to recruit ATM. Have there been reports that MRN recognizes and binds to SSBs?

We thank the reviewers to point out these important references that were missing in the previous draft. Indeed, independent biochemistry experiments from several laboratories showed that purified MRE11 proteins from various species (human, yeast, etc.) binds to ssDNA as well as dsDNA (Nucleic Acids Res. 2001 Mar 15; 29(6): 1317--1325; Cell, 95 (1998), pp. 705--716); Genes Dev., 13 (1999), pp. 1276--1288). We have now included these references in our manuscript (subsection "ATM-KD blocks replication-dependent removal of Topo-isomerase I DNA adducts at the step of strand cleavage", third paragraph).

Moreover, these experiments also revealed that the affinity of Mre11 to ssDNA is even higher than its affinity to dsDNA. Moreover, Mre11 binds to both linear and circular form of ssDNA, suggesting the binding between MRE11 to ssDNA does not require free DNA ends. This is likely the structure that is generated at stalled replication fork after the leading and lagging strand are uncoupled (see [Figure 5C](#fig5){ref-type="fig"} blue dash box).

Correspondingly, recent studies using the iPOND technology have identified MRE11 at the stalled forks in vivo(Sirbu et al., 2011). We have now discussed these important supporting references in the third paragraph of the subsection "ATM-KD blocks replication-dependent removal of Topo-isomerase I DNA adducts at the step of strand cleavage" and the Discussion section.

5\) In the same figure, it looks like upon CPT treatment, ATM inhibitor in cells expressing nuclease-deficient MRE11 abolished gH2AX formation (indicative of DSB generation) while in wild type MRE11-expressing cells only partially reduced gH2AX. Is the difference reproducible? If so, this would suggest that MRE11 nuclease also contribute gH2AX (DSB) formation in CPT-treated ATM^KD/-^cells (again, if MRN binds to SSB). What is the likely explanation?

In current [Figure 7A](#fig7){ref-type="fig"} (previous [Figure 5D](#fig5){ref-type="fig"}), ATM kinase inhibitors abolished CPT induced DSBs in Mre11 nuclease deficient cells more effectively than in *Mre11+/-* cells. We now provided two independent biological replicates of this experiments (current [Figure 7---figure supplement 1B and 1C](#fig7s1){ref-type="fig"}). This result is robust and reproducible. Several possible explanations exist. First, MRE11 nuclease activity might help to cleave the DNA and therefore release the stalled Atm-KD (possibly together with MRN complex) from the replication forks and in turn "allow" CPT induced strand cleavage. In this context, lack of Sae2, a potent modulator of MRE11 nuclease activity, cause hyper activation of Tel1 (yeast orthology of ATM). Two recent papers have identified Mre11 mutants that suppresses persistent ATM (Tel1 in yeast) mediated checkpoint activation in Sae2 deficient cells (Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):E1880-7; and EMBO J. 2015 Jun 3;34(11):1509-22.) (Discussion section), suggesting Mre11 and its nuclease activity might contribute to the termination of ATM signaling. Another not mutually exclusive possibility would be, Mre11 nuclease activity directly contribute to fork cleavage, which in turn resolves the stalled replication fork. In this context, we found that two Mre11 nuclease inhibitors -- PFM01 and Mirin both reduced CPT-induced gH2AX in *Atm~+/+~* and *Atm~-/-~* cells. This data is now included in [Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"} and discussed in the Discussion section. However, given the toxicity of the Mre11 nuclease inhibitors in general, further experiments would be necessary to solidify the role of MRE11 nuclease activity in CPT induced double stand breaks.

*Other Specific Issues (in no particular order):*

1\) The graph in [Figure 2D](#fig2){ref-type="fig"} indicates that the incidence of Thymic lymphoma is about 65%, not 75% as indicated in the text. The difference between the VN and VKD animals is now not very different. Also, were tests for statistical significance performed on all these comparisons?

We apologize for this error. We mean that "the incidence of lymphomas (not thymic lymphomas) is 75% in VKD vs. 56% in VN". We have now correct this. Since there is no B cell lymphomas in VN mice, we compared the kinetic of "thymic lymphomas" in VKD vs. in VN mice using Mantel-Cox/log rank test and the p=0.03 (subsection "Expression of Atm-KD is more oncogenic than loss of Atm", second paragraph and [Figure 2E](#fig2){ref-type="fig"} legend).

2\) To be convincing, rather than showing four examples, the spleen weight of appropriate numbers of mice should be reported for [Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}.

We performed additional biological repeats for the isogenic *ATM~C/C~* and *ATM~-/-~* activated Notch- drive leukemia. The results supported our initial observation. The statistical analyses as well as the presentative histology figures are now included in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. Given the additional figure panels, we have moved the data related to the isogenic leukemia to [Figure 4](#fig4){ref-type="fig"} (from [Figure 3](#fig3){ref-type="fig"} in the original submission) and the subsequent figures were also shifted correspondingly.

3\) The results in [Figure 4A](#fig4){ref-type="fig"} (particularly the comparison with ATM^-/-^) need to be quantified in multiple experiments to be convincing.

We have now performed two additional biological repeats on independent derived *Atm~KD/-~*and *Atm~-/-~* MEF lines. The results are shown in [Figure 5---figure supplement 1A and 1B](#fig5s1){ref-type="fig"}. Two different exposures for each experiments were also shown. Given the intrinsic error of densitometry analyses (e.g.which exposure to use and how to subtract backgrounds), we felt that the differences are robust enough and three independent biological replicates would make this point stronger.

4\) Why is there no effective suppression of CPT-induced DSB formation in the Mre11^+/-^ cells in [Figure 5D](#fig5){ref-type="fig"}?

While Mre11~-/-~ is cell lethal and embryonic lethal, Mre11~+/-~ mice and cells have not measurable repair defects, suggesting one copy of Mre11 is sufficient to support normal function of Mre11 (Buis et al., 2008). We have now showed three biological replicates on this experiments ([Figure 7A](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1B and 1C](#fig7s1){ref-type="fig"}). Together, these experiments indicate that ATM kinase inhibitor does reduce CPT induced g-H2AX in Mre11~+/-~ cells.

5\) The ATM kinase dead mutation generated by Canman et al. contained two missense mutations, not a single N2875K mutation.

We have now made this clear in the text (subsection "Cancer-associated ATM mutations are enriched for kinase domain missense mutations"). N2875K is one of the two mutations (N2875K and D2870A) engineered into the ATM KD allele in the Canman et al. paper.

6\) The nomenclature for the mice needs to be clarified in the Abstract and Introduction. The meaning of Atm^C^ is not clear in the Abstract.

Given the 150 words limited for the abstract, we have now replaced *Atm~C/KD~*and *Atm~C/C~* in the Abstract with "Atm-proficient" and further define the nomenclature in the main text.

7\) There are grammatical errors that should be corrected.

We have proofread the manuscript to minimize this issue.

8\) Work by Katyal S et al. (published in 2014 on Nature Neuroscience), which was referenced by the authors, showed that ATM depletion inflicted more DNA damage upon CPT treatment than inhibition of ATM kinase activity in quiescent astrocyte. However, the authors reported here that ATM^KD/-^ cells are more sensitive to CPT than ATM^-/-^ cells. What may contribute to this difference? Cell type, cell cycle (proliferating vs. quiescent) or others.

Two studies, including the Katyal S et al. and an earlier study by Alagoz, M et Al. (Alagoz et al., 2013; Katyal et al., 2014), described defects in Top1cc metabolism in *Atm~-/-~* neuronal cells, especially astrocytes. We would like to point out that the Top1cc assay in current [Figure 5A](#fig5){ref-type="fig"} (previously [Figure 4A](#fig4){ref-type="fig"}) and the biological repeats (current [Figure 5---figure supplement 1A and 1B](#fig5s1){ref-type="fig"}) all showed that *Atm~-/-~* MEFs accumulates higher levels of Top1cc than *Atm~+/+~* cells, especially at high CPT dose (15µM), consistent with the results from astrocytes. In this context, cell type alone is insufficient to explain these differences.

What is unique to our study is, we found that *Atm~KD/-~*cells accumulate much higher levels of Top1cc than *Atm~-/-~* (and *Atm~+/+~*) cells. In addition to the high CPT dose used in previous studies (15µM, IC50 for CPT in WT cells is \~ 0.01uM), we showed that *Atm~KD/-~*cells accumulate Top1cc at 0.1µM CPT ([Figure 5A](#fig5){ref-type="fig"}). At the mechanistic level, we identified that *Atm~KD/-~* cells, but not *Atm~-/-~* cells, have a defects in CPT induced DSB formation (gH2AX). [Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"} shows that CPT induced DSBs formation occurs predominantly in S phase cells, while previous studies were primarily conducted in "quiescent astrocytes", which would not uncover replication associated Top1cc removal defects. Based on this, we suggested that the difference is likely to be cell cycle dependent.

In this context, Katyal, S et al. suggests that *Atm~-/-~* cells have a defect in CPT induced Top1- proteolytic degradation astrocytes. Yet, we found that CPT induced degradation of full length Topo1 is not measurably affected in proliferating *Atm~KD/-~*or *Atm~-/-~* MEFs. Studies from *Xenopus* extracts showed that collision with replication forks induce proteolytic degradation of proteins covalently linked to DNA (e.g. Top1cc) (Duxin et al., 2014). While how ATM affects in CPT induced Top1 degradation in astrocytes are yet to be determined, the robust replication dependently proteolytic program might explain the lack of the proteolytic defects in proliferating *Atm~KD/-~*and *Atm~-/-~* MEFs in our study. Together, our data support a model in which ATM is recruited to CPT induced stalled replication forks, where auto-phosphorylation of ATM is necessary to license strand cleavage. In this case, the absence of ATM (*Atm^-/-^*) would not pose an inhibitory effect. Finally, since the cancer cells were preferentially targeted by "proliferation/replication" specific damages, the replication associated Top1cc removal defects in *Atm~KD/-~*cells uncovered in our study are particularly relative to cancer therapy. We now discussed this in detail in the subsection "ATM-KD blocks replication-dependent removal of Topo-isomerase I DNA adducts at the step of strand cleavage".

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:*

*First, in the current [Figure 7A](#fig7){ref-type="fig"}, the authors showed that Mre11 nuclease activity (Mre11+/-) contributes to CPT-induced DSB generation in the presence of ATM-KD protein. Two additional biological replicates were provided in [Figure 7---figure supplement 1B and 1C](#fig7s1){ref-type="fig"}. However, the data presented in the supplemental figures are not convincing -- there is no more gH2AX in Mre11+/- than in Mre11H129N/-. There is a very little gH2AX induction in these two additional experiments, compared to [Figure 7A](#fig7){ref-type="fig"}. Therefore, it is not straightforward to conclude whether the nuclease activity of Mre11 also contribute to CPT-induced DSB generation in this context. The author should re-phase accordingly.*

We now emphasized -- "further investigation is needed to clarify this issue". But we also would like to point out that in the first revision of the manuscript -- the possible role of the MRE11 nuclease activity is *only* mentioned in the Discussion and not presented as a "conclusion". Specifically, in the Discussion, we cautiously stated that "...suggesting that Mre11 nuclease activity might contribute to the removal of ATM or the termination of ATM activation". This is *not* a conclusion of our study. In fact, in the revision, we already stated at the end of discussion about Mre11 "...further experiments are warranted to understand the molecular details of MRE11 function in fork cleavage" (Discussion, second paragraph). We only try to suggest this as a possibility (among others) that could explain the data we saw.

*The second point regards the lack of RAD51 foci in ATMKD cells treated with CPT. The authors attributed this observation to the lack of DSB generation ATMKD cells, rather than impaired RAD51 loading. While this statement is valid with the support the absence (or reduced number) of gH2AX foci and neutral comet assay, the possibility of defective RAD51 loading should not be excluded. The authors stated in the response to reviewer\'s comment that the ssDNA at stalled replication fork would not lead to RAD51 loading. However, two independent studies have directly or indirectly shown that RAD51 is present at stalled replication forks to promote fork reversal or protect the integrity of nascent DNA strands (Zellweger R et al., JCB, 2015 and Schlacher K et al., Cell, 2011). The later study actually proposed that the stability of RAD51 filament, rather than RAD51 \"loading\", is important for protecting nascent DNA at stalled fork. Whether RAD51 loading is an issue or not does not affect the core value of this manuscript, but it would be nice if the authors could make a minor revision to include all possibilities.*

We have now cited both references (Zellweger R et al., JCB, 2015 and Schlacher K et al., Cell, 2011) mentioned by the reviewers. We noted that we had already cited Zellweger R et al., JCB, 2015 in our first revision. We now further clarify that we could only exclude a "general" defect that affecting RAD51 loading to "resected DSBs" in *Atm^KD/-^*cells (subsection "ATM-KD blocks replication-dependent removal of Topo-isomerase I DNA adducts at the step of strand cleavage", second paragraph), since IR induced RAD51 foci formation is *not* significantly reduced in *Atm^KD/-^*cells. We also added discussion that explores the possibility that Rad51 loading or stability at the stalled replication fork might be regulated differently than those occurred at the resected DSBs (from IR) (Discussion, fourth paragraph).
